Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
APVO 
Aptevo Therapeutics Inc (APVO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: APVO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $420
1 Year Target Price $420
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -54.71% | Avg. Invested days 11 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.59M USD | Price to earnings Ratio - | 1Y Target Price 420 |
Price to earnings Ratio - | 1Y Target Price 420 | ||
Volume (30-day avg) 1 | Beta 5.63 | 52 Weeks Range 1.61 - 381.10 | Updated Date 08/29/2025 |
52 Weeks Range 1.61 - 381.10 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2680.54 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-11 | When - | Estimate -0.25 | Actual -8.4 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -99.45% | Return on Equity (TTM) -437.34% |
Valuation
Trailing PE - | Forward PE 3.94 | Enterprise Value 388460 | Price to Sales(TTM) 1.61 |
Enterprise Value 388460 | Price to Sales(TTM) 1.61 | ||
Enterprise Value to Revenue 0.12 | Enterprise Value to EBITDA 0.39 | Shares Outstanding 3287920 | Shares Floating 3287885 |
Shares Outstanding 3287920 | Shares Floating 3287885 | ||
Percent Insiders - | Percent Institutions 0.38 |
Upturn AI SWOT
Aptevo Therapeutics Inc
Company Overview
History and Background
Aptevo Therapeutics Inc. was founded in 2016 as a spin-off from Emergent BioSolutions. It focuses on developing novel immunotherapies for cancer and autoimmune diseases. The company utilizes its ADAPTIR protein therapeutic platform to create bispecific antibodies and other targeted therapies.
Core Business Areas
- Oncology: Developing immunotherapies for various cancer types, focusing on bispecific antibodies that redirect the immune system to target and destroy cancer cells.
- Hematology: Focus on products for hematologic diseases, especially autoimmune related.
- ADAPTIR Platform: Licensing and further developing its ADAPTIR modular protein technology platform.
Leadership and Structure
Marvin White is the President and CEO. The company has a board of directors overseeing strategic direction and governance. Aptevo has departments for R&D, clinical development, manufacturing, and commercial operations.
Top Products and Market Share
Key Offerings
- Ruxience (rituximab-pvvr): Biosimilar to Rituxan, used to treat certain cancers and autoimmune diseases. Although marketed by another company, Aptevo receives royalties. Market share data is available for the broader rituximab market, but specific Ruxience share information attributable to Aptevo's royalty stream is not publicly disclosed. Competitors include Biogen and Celltrion (Truxima, Rixathon), Sandoz (biosimilar).
- Apex-DUET: Aptevo's proprietary bispecific antibody for immuno-oncology. Currently in preclinical development. This product is to treat several solid tumors. Competitors include many pharmaceutical companies with immuno-oncology pipelines such as Regeneron, Roche and Genmab.
Market Dynamics
Industry Overview
The biopharmaceutical industry is experiencing rapid growth, driven by advancements in immunotherapy and targeted therapies. There is increasing demand for novel cancer treatments and autoimmune disease therapies.
Positioning
Aptevo is positioned as a biotechnology company focused on developing innovative immunotherapies. Its ADAPTIR platform offers a competitive advantage in creating bispecific antibodies.
Total Addressable Market (TAM)
The total addressable market for cancer immunotherapies is estimated to reach hundreds of billions of dollars. Aptevo's TAM is defined by its ability to develop successful drugs using the ADAPTIR platform for specific cancer indications, with a potential worth of billions, contingent on successful clinical trials and regulatory approval.
Upturn SWOT Analysis
Strengths
- ADAPTIR platform technology
- Expertise in bispecific antibody development
- Potential for royalty revenue from biosimilars
- Focus on high-growth immunotherapy market
Weaknesses
- Limited financial resources
- Dependence on successful clinical trial outcomes
- Reliance on partners for commercialization
- High risk inherent in drug development
Opportunities
- Strategic partnerships with larger pharmaceutical companies
- Expansion of ADAPTIR platform to new therapeutic areas
- Positive clinical trial results for pipeline candidates
- Increased demand for targeted immunotherapies
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and approval delays
- Failure of clinical trials
- Patent challenges and intellectual property disputes
Competitors and Market Share
Key Competitors
- REGN
- GTHX
- BMY
- MRK
- Roche Holding AG (ROG.SW)
Competitive Landscape
Aptevo faces intense competition from larger pharmaceutical companies with greater resources. Its ADAPTIR platform and focus on bispecific antibodies could provide a competitive edge. However, financial constraints and reliance on partners present challenges.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by R&D progress and partnership developments.
Future Projections: Future growth is tied to the successful development and commercialization of its pipeline candidates. Analyst estimates vary depending on the perceived potential of the ADAPTIR platform and the clinical progress of its drugs. Data will be shown here once found
Recent Initiatives: Recent initiatives include advancing Apex-DUET and other ADAPTIR-based immunotherapies through preclinical and clinical development.
Summary
Aptevo is a biopharmaceutical company focused on innovative immunotherapies using its ADAPTIR platform. It has potential for growth driven by its pipeline candidates, but also faces risks related to clinical trials, regulatory approvals, and competition. Its strengths lie in its technology and targeted approach, while weaknesses include financial constraints and dependence on partners. The future will depend on its ability to execute its clinical development plan and secure strategic collaborations.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data and financial performance metrics are estimates based on available information and may not be precise. Investment in APVO involves significant risks, including the risk of loss of investment.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aptevo Therapeutics Inc
Exchange NASDAQ | Headquaters Seattle, WA, United States | ||
IPO Launch date 2016-07-20 | President, CEO & Director Mr. Marvin L. White | ||
Sector Healthcare | Industry Biotechnology | Full time employees 37 | Website https://aptevotherapeutics.com |
Full time employees 37 | Website https://aptevotherapeutics.com | ||
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.